Go to deals
Healthcare | Private Equity

Empirical Bioscience has been acquired by Fortis Life Sciences

The owner of Empirical Bioscience has sold the company to Fortis Life Sciences.

Empirical Bioscience is a leading developer and manufacturer of enzymes, proteins and reagents for molecular biology and life science applications. Empirical focuses on supplying premium, quality and custom-configured products to the life sciences industry for both research and commercial applications. The company has a comprehensive library of products that can be readily configured to customer specifications and offers technical support to assist with the development and launch of assays and products.

Fortis Life Sciences is a strategic platform providing capital, expertise and operational resources enabling the growth and success of founder-led life science tools companies.

One of Oaklins’ teams in the USA served as the financial advisor to Empirical Bioscience in its sale to Fortis Life Sciences.

Parties

Talk to the deal team

Bradford A. Adams

Managing Director
Boston, United States
Oaklins TM Capital

Michael S. Goldman

Managing Director
New York, United States
Oaklins TM Capital

Harrison P. Boeschenstein

Associate
Boston, United States
Oaklins TM Capital

Related deals

Bolster Investment Partners has acquired a majority stake in Eternal Sun
Private Equity | Energy

Bolster Investment Partners has acquired a majority stake in Eternal Sun

Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.

Learn more
Cerbios-Pharma has been acquired by HAS Healthcare
Healthcare

Cerbios-Pharma has been acquired by HAS Healthcare

Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.

Learn more
iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
Private Equity | Construction & Engineering Services | Energy | TMT

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.

Learn more